Abbott India Ltd (ABBOTINDIA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Abbott India Ltd on NSE and BSE, with an AI summary of each filing.
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 05 Nov 2026, 5:30 am
Abbott India Board Meeting Scheduled on 5th Nov'26 for Q2 Earnings Abbott India Limited announced that its Board of Directors will meet on 5th Nov'26 to consider and approve the unaudited financial results for the second quarter and half year ended 30th Sep'26. In accordance with SEBI Insider Trading Regulations, the company's trading window for designated persons remains closed from 1st Oct'26 to 7th Nov'26, both days inclusive.
Resignation of Company Secretary and Compliance Officer of the Company.
Change in Management · 08 Sept 2026, 1:36 am
Abbott India Announces Resignation of Company Secretary and Compliance Officer Abbott India Limited has announced the resignation of Ms. Sangeeta Shetty from the position of Company Secretary and Compliance Officer (Key Managerial Personnel) to pursue an external career opportunity. The Board of Directors has accepted her resignation, and she will be relieved from her duties effective from the close of business hours on 28th Oct'26. The company confirmed that there are no other material reasons for her departure.
Voting Results along with Consolidated Scrutinizer''s Report for the 82nd Annual General Meeting held on August 13, 2026.
Annual General Meeting · 14 Aug 2026, 11:49 pm
Proceedings of 82nd Annual General Meeting of the Company.
Annual General Meeting · 13 Aug 2026, 10:48 pm
Unaudited financial results for the quarter ended June 30, 2026.
Financial Result · 13 Aug 2026, 12:48 am
Abbott India Q1FY27: Strong Profit Growth Driven by Operational Efficiency Abbott India reported strong Q1FY27 results with Profit After Tax (PAT) at ₹428.5 cr, up 17.1% YoY and 8.5% QoQ. Revenue from operations grew 4.3% YoY to ₹1,813.7 cr. Profit before tax (PBT) rose 16.0% YoY to ₹572.2 cr, driven by a slight dip in total expenses to ₹1,316.8 cr from ₹1,318.1 cr YoY, despite higher raw material costs. Basic Earnings Per Share (EPS) for the quarter stood at ₹201.66, a significant 17.1% increase from ₹172.17 in Q1FY26.
Outcome of Board Meeting
Outcome · 13 Aug 2026, 12:15 am
Abbott India Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Crore) ■ Revenue: 1,814 (+4.3% YoY | +6.1% QoQ) ■ EBITDA: 523 (+17.3% YoY | +8.7% QoQ) ■ EBITDA Margin (%): 28.8 (+318 bps YoY | +68 bps QoQ) ■ PAT: 429 (+17.1% YoY | +8.5% QoQ) ■ EPS (INR): 201.7 (+17.1% YoY | +8.5% QoQ)
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 12 Aug 2026, 5:30 am
Abbott India Board Meeting Scheduled for Q1FY27 Results Abbott India has scheduled a Board of Directors meeting for Wed, 12th Aug'26, to consider and approve its unaudited financial results for the quarter ending 30th Jun'26. In line with insider trading regulations, the company's trading window for insiders will remain closed from Wed, 1st Jul'26 to Fri, 14th Aug'26, inclusive. This announcement is a key procedural step ahead of the Q1FY27 earnings release, which will provide insight into the company's initial performance for the fiscal year.
Communication providing the weblink including path of Annual Report.
Annual Report · 20 Jul 2026, 9:55 pm
Submission of Business Responsibility and Sustainability Report for the Financial Year 2025-26.
Others (Uncategorized) · 20 Jul 2026, 9:36 pm
Abbott India Submits Business Responsibility and Sustainability Report for FY25-26 Abbott India filed its Business Responsibility and Sustainability Report for FY25-26 on 20th Jul'26. The company reported a turnover of ₹6,846.10 crores and net worth of ₹4,774.19 crores. Exports contributed 1.2% to total turnover. For FY25-26, total energy consumption stood at 45,138.49 GJ, with 39.73% from renewable sources. Key initiatives included launching Extensior (semaglutide) and Ezybixy (elobixibat), and advancing CSR projects in healthcare access. Regulatory actions included a ₹2.40 crore GST penalty, which is under appeal, and a ₹0.02 crore RBI compounding amount.
Notice of the 82nd Annual General Meeting of the Company to be held on August 13, 2026.
Annual General Meeting · 20 Jul 2026, 9:25 pm
Annual Report for the financial year 2025-26.
Others (Uncategorized) · 20 Jul 2026, 7:48 pm
Communication to Shareholders - Intimation about Tax Deduction at Source on Dividend.
Dividend · 15 Jun 2026, 8:14 pm
Abbott India Announces FY26 Dividend and Tax Withholding Details Abbott India's board recommended a final dividend of ₹525 and a special dividend of ₹131 per share for FY26. The record date is set for 24 Jul'26, with payment on or after 18 Aug'26, pending shareholder approval at the 13 Aug'26 AGM. Dividends are taxable for shareholders, and the company will deduct Tax at Source (TDS). Shareholders must submit required documents by 24 Jul'26 to ensure appropriate TDS rates are applied, which vary based on residency and documentation provided.
Appointment of Senior Management Personnel.
Change in Management · 25 May 2026, 10:56 pm
Abbott India Appoints New Associate Director - Operations Abbott India has appointed Ms. Swati Pathak as Associate Director - Operations and a member of the Senior Management team, effective from 1st Jun'26. With over 22 years of experience, she previously led the NPI & TAS function for Abbott's Specialty Care business in India, establishing NPI as a key growth driver. Ms. Pathak has been with Abbott since 2007 in various R&D, project management, and portfolio strategy roles, contributing to incremental growth and leading major new product launches. She is not related to existing management.
Record Date for Dividend
Dividend · 12 May 2026, 3:46 am
Abbott India Sets Record Date for FY26 Final Dividend Abbott India has fixed Friday, 24 Jul'26, as the record date to determine shareholder eligibility for the final dividend for the financial year ending 31 Mar'26. The dividend payment, subject to approval at the upcoming 82nd Annual General Meeting, is scheduled to be paid on or after Tuesday, 18 Aug'26. Shareholders whose names are on the register as of the record date will be entitled to the dividend. The specific dividend amount per share was not disclosed in this filing.
Audited Financial Results for the quarter and year ended March 31, 2026
Financial Result · 12 May 2026, 3:42 am
Abbott India Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Crore) ■ Revenue: 1710 (+6.5% YoY | -0.8% QoQ) ■ EBITDA: 481 (+12.2% YoY | +3.7% QoQ) ■ EBITDA Margin (%): 28.1 (+142 bps YoY | +125 bps QoQ) ■ PAT: 395 (+7.6% YoY | +5.0% QoQ) ■ EPS (INR): 185.9 (+7.6% YoY | +5.0% QoQ)
Outcome of Board Meeting
Outcome · 12 May 2026, 3:34 am
Abbott India Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Crore) ■ Revenue: 1710 (+6.5% YoY | -0.8% QoQ) ■ EBITDA: 481 (+12.2% YoY | +3.7% QoQ) ■ EBITDA Margin (%): 28.1 (+142 bps YoY | +125 bps QoQ) ■ PAT: 395 (+7.6% YoY | +5.0% QoQ) ■ EPS (INR): 185.9 (+7.6% YoY | +5.0% QoQ)
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2026 ,inter alia, to consider and approve Audited Financial Results of the ....
Intimation · 11 May 2026, 5:30 am
Abbott India Board Meeting Scheduled for Financial Results and Dividend Abbott India (Scrip Code: 500488) has scheduled a Board of Directors meeting on Mon, May 11, '26. The agenda includes the approval of audited financial results for the quarter and financial year ended Mar 31, '26. The board will also consider the recommendation of a final dividend for the same financial year. In connection with this, the trading window for insiders is closed from Apr 01, '26, to May 13, '26, inclusive.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 5:05 pm
Abbott India Not Classified as Large Corporate for FY27 Abbott India (Scrip: 500488) has officially informed the BSE that it does not meet the criteria to be classified as a Large Corporate as of 31 Mar'26. According to the filing on 30 Apr'26, the company reported NIL outstanding borrowings as of the assessment date. Consequently, the SEBI framework requiring large corporates to raise a portion of their incremental borrowings via debt securities is not applicable to Abbott India for the upcoming financial year, indicating a strong, debt-free balance sheet.
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Change in Management · 22 Apr 2026, 6:02 pm
Abbott India Announces Board and Senior Management Changes Abbott India announced multiple board and management changes. Anisha Motwani’s term as Independent Director ends on Apr 24, '26. Alison Davies has resigned as Director effective Apr 22, '26. Neeraj Jain is appointed as an Additional and Independent Director for a 3-year term from Apr 25, '26, while James Wenner is appointed as an Additional (Non-Executive) Director from Apr 23, '26. In senior management, Tushar Singh, Plant Director - Goa, will move to another affiliate from Jun 1, '26, and be replaced by Amol Metkar.
Outcome of Board Meeting.
Others (Uncategorized) · 22 Apr 2026, 5:59 pm
Abbott India Announces Multiple Board and Senior Management Changes Abbott India announced several leadership changes effective Apr'26. Anisha Motwani's term as Independent Director ends on Apr 24, while Alison Davies has resigned as Director, effective Apr 22. Neeraj Jain will join as an Independent Director from Apr 25, and James Wenner as an Additional (Non-Executive) Director from Apr 23. In senior management, Tushar Singh, Plant Director - Goa, will move to another Abbott affiliate, ceasing his role on May 31. Amol Metkar has been appointed as the new Plant Director - Goa, effective Jun 1.
Abbott partners with Novo Nordisk India to launch Extensior, broadening access to Semaglutide (Ozempic) for advanced diabetes management.
Press Release · 27 Feb 2026, 9:10 pm
Abbott India Partners with Novo Nordisk to Launch Semaglutide Brand Abbott India announced on 27 Feb'26 a strategic partnership with Novo Nordisk India to commercialize Semaglutide (Ozempic) under the brand name Extensior for type 2 diabetes. This collaboration combines Novo Nordisk's GLP-1 leadership with Abbott's extensive distribution network in India. The move aims to broaden access to the high-demand diabetes therapy beyond regions Novo Nordisk currently serves. Extensior is a second brand of Ozempic, targeting India's rapidly growing diabetes market, which has over 100 million patients and national expenditure exceeding USD 9.8 billion.
Unaudited Financial Results of the Company for the quarter ended December 31, 2025.
Financial Result · 12 Feb 2026, 7:03 pm
Abbott India Q3FY26: Revenue Rises 6.8% YoY While Profit After Tax Declines Abbott India reported Q3FY26 results with Revenue from Operations at ₹1,724.04 crore, up 6.8% YoY but down 1.9% QoQ. Profit After Tax (PAT) stood at ₹375.96 crore, a 4.2% YoY increase, but fell 9.5% QoQ from ₹415.27 crore. The decline was impacted by a one-time charge of ₹35.10 crore due to new labour code implications, which increased employee benefit expenses. Profit Before Tax was ₹508.98 crore, a 4.4% YoY rise but a 6.8% QoQ decrease. EPS for the quarter was ₹176.92.
Outcome of Board Meeting.
Outcome · 12 Feb 2026, 6:56 pm
Abbott India Limited - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Crore) ■ Revenue: 1724 (+6.8% YoY | -1.9% QoQ) ■ EBITDA: 463 (+6.3% YoY | -7.7% QoQ) ■ EBITDA Margin (%): 26.9 (-13 bps YoY | -170 bps QoQ) ■ PAT: 376 (+4.2% YoY | -9.5% QoQ) ■ EPS (INR): 176.9 (+4.2% YoY | -9.5% QoQ)
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve Unaudited Financial Results of ....
Intimation · 12 Feb 2026, 5:30 am
Abbott India Board to Approve Q3FY26 Results on 12-Feb'26 Abbott India Limited has scheduled a Board of Directors meeting for Thu, 12-Feb'26. The primary agenda is to consider and approve the Unaudited Financial Results for the quarter and nine months ending 31-Dec'25. In compliance with insider trading regulations, the company's trading window for designated persons has been closed since 01-Jan'26 and will reopen 48 hours after the financial results are declared. This meeting is crucial for assessing the company's Q3 performance and year-to-date financial health.
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Others (Uncategorized) · 31 Dec 2025, 5:58 pm
Abbott India Receives INR 2.4 Crore GST Penalty Order Abbott India received an order on 30 Dec'25 from the GST & Central Excise, Mumbai, levying a penalty of INR 2.40 crore. The penalty pertains to the disallowance of Input Tax Credit for the financial years FY19, FY20, FY22, and FY24. The company states there is no material financial impact and believes the demand is not maintainable. It plans to file an appeal against the order.